NexImmune (OTCMKTS:NEXI – Get Free Report) is expected to be announcing its results on Tuesday, November 17th. Analysts expect NexImmune to post earnings of ($13.25) per share for the quarter.
NexImmune Price Performance
NexImmune has a 1-year low of $0.00 and a 1-year high of $2.17.
About NexImmune
NexImmune, Inc. was a biotechnology company focused on developing cell-based immunotherapies for cancer. Its Artificial Immune Modulation (AIM) platform was designed to activate and expand T cells that recognize specific cancer-associated targets. The company’s investigational programs included NEXI-001, a T-cell therapy for acute myeloid leukemia, and NEXI-002, a program for multiple myeloma. NexImmune was based in Gaithersburg, Maryland, and its therapies were in clinical development rather than commercially available.
Featured Stories
- Five stocks we like better than NexImmune
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
